Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Degarelix has a real but limited body of human research.
- 167 registered studies in total.
- 20 are still enrolling people, so this is active research, not just history.
What kind of research
- 151 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 31,267 people took part in those.
- A further 16 studies only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.
How far along it is
- 47 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 39 have published results in the medical literature that anyone can read.
- The research spans 46 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 167 of 167 trials for Degarelix.
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Prostate Cancer · Localized Prostate Carcinoma
CAMO959A12103
Novartis Pharma AG
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Castration-resistant Prostate Cancer
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Prostate Cancer
CJSB462C12201
Novartis Pharma AG
Metastatic hormone-sensitive prostate cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Castration-resistant Prostate Cancer
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Prostate Cancer
EORTC-2238-GUCG
European Organisation For Research And Treatment Of Cancer
Metastatic hormone naïve prostate cancer (mHNPC)
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
High Risk Prostate Carcinoma · Localized Prostate Adenocarcinoma · Stage I Prostate Cancer AJCC v8 · Stage II Prostate Cancer AJCC v8
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Metastatic Castration Sensitive Prostate Cancer
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Novartis Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
UC-GTG-2306
Unicancer
Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Debio 4228-201
Debiopharm International SA
advanced prostate cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis Pharmaceuticals
Metastatic Neuroendocrine Prostate Cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
University Health Network, Toronto
Prostate Cancer
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic
Recurrent Castration-Sensitive Prostate Carcinoma · Recurrent Prostate Cancer · Castration-resistant Prostate Cancer · Biochemically Recurrent Prostate Carcinoma
Cardiometabolic Consequences of the Loss of Ovarian Function
University of Colorado, Denver
Menopause · Estrogen Deficiency · Aging · Adiposity
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
M.D. Anderson Cancer Center
Prostate Cancer
CAAA617B12203
Novartis Pharma AG
PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
Memorial Sloan Kettering Cancer Center
Prostate Cancer
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
Cancer Research Antwerp
Prostate Cancer
CAAA802A12101
Novartis Pharma AG
PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
ETHAN - ET for Male BC
Jose Pablo Leone
Male Breast Cancer · Hormone Receptor-positive Breast Cancer · Hormone Receptor Negative Breast Carcinoma
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
Brown University
Urothelial Carcinoma Bladder · Androgen Receptor Positive
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Praful Ravi, MB BCHir, MRCP
Metastatic Prostate Cancer · Non-metastatic Prostate Cancer · Prostate Cancer
Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer
Turku University Hospital
Localized Prostate Carcinoma · Castration-Naive Prostate Cancer · Intermediate Risk Prostate Cancer · Prostate Cancer
Effect of neoadjuvant Degarelix on MRI-guided transurethral ultrasound ablation in patients with intermediate-risk prostate cancer: A pilot study
Turku University Central Hospital
Intermediate-risk prostate cancer
IB 2021-03
Institut Bergonie
Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Metastatic Castration Sensitive Prostate Cancer (mCSPC) · Metastatic Castration Resistant Prostate Cancer (mCRPC)
Prostate Medication, Metabolism and Gut Microbiota
Turku University Hospital
Prostatic Hyperplasia · Prostate Cancer
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Fudan University
Prostate Cancer
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer · Stage IV Prostate Cancer
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
University of Wisconsin, Madison
Prostate Cancer
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Prostate Adenocarcinoma
Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)
University of Colorado, Denver
Menopause · Estrogen Deficiency · Women · Aging
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Alliance for Clinical Trials in Oncology
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Adenocarcinoma · Stage IV Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
VA Office of Research and Development
Prostate Cancer · Oligometastasis · Oligorecurrence · Recurrent Prostate Cancer
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Castration-Sensitive Prostate Carcinoma · Metastatic Prostate Adenocarcinoma · Stage IV Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Cancer Institute (NCI)
Cancer Of Prostate · Prostate Neoplasms
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Prostate Adenocarcinoma · Stage III Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
M.D. Anderson Cancer Center
Biochemically Recurrent Prostate Carcinoma · Metastatic Prostate Carcinoma · Oligometastatic Prostate Carcinoma · Stage IV Prostate Cancer AJCC v8
67652000PCR3002
Janssen - Cilag International
Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ECOG-ACRIN Cancer Research Group
Biochemically Recurrent Prostate Carcinoma · Metastatic Prostate Carcinoma · Prostate Adenocarcinoma · Stage IVB Prostate Cancer AJCC v8
Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma
Centre Leon Berard
Prostate Adenocarcinoma
Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization
VA Office of Research and Development
COVID-19
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Xiao X. Wei, MD
Hormone Sensitive Prostate Cancer · Prostate Adenocarcinoma · Metastasis Prostate Adenocarcinoma
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Columbia University
Prostate Cancer
Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer
Aarhus University Hospital
Bladder Cancer · Radiation Therapy Complication · Quality of Life
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
Wonju Severance Christian Hospital
Prostatic Neoplasms
Cardiovascular Events in GnRH Agonist vs. Antagonist
Rabin Medical Center
Hormone Sensitive Prostate Cancer · Prostate Cancer · Cardiac Event
Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer
Assistance Publique - Hôpitaux de Paris
Invasive Ductal Breast Carcinoma
Bioenergetic Effects of Aging and Menopause (BEAM)
University of Colorado, Denver
Menopause · Obesity, Abdominal · Aging · Weight Gain
Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
Brigham and Women's Hospital
Prostate Cancer
The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer
Lund University
Prostate Cancer Recurrent
FIRMAGON® Intensive Drug Monitoring
Ferring Pharmaceuticals
Prostate Cancer
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Mark Stein
Prostate Cancer Metastatic
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer
Turku University Hospital
Metastatic prostate cancer, Prostate cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
Cancer Research Antwerp
Cancer of Prostate
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
Universitaire Ziekenhuizen KU Leuven
Prostate Cancer · Neoadjuvant Therapy · Androgen Antagonists · Prostatectomy
64091742PCR3001
Janssen - Cilag International
Metastatic Prostate Cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer
Turku University Hospital
Prostate Cancer
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Mark Stein
Prostate Cancer · Adenocarcinoma of the Prostate
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
Castration Levels of Testosterone · Metastatic Prostatic Adenocarcinoma · Stage IV Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Prostate Adenocarcinoma
A New Revolutionary 3-Injection- Protocol in Infertile Women
Assisting Nature
Infertility, Female
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function
University of Colorado, Denver
Cognitive Impairment · Estrogen Deficiency · Menopause · Endothelial Dysfunction
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
University of Wisconsin, Madison
Prostate Cancer
EORTC-1532-GUCG: A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer.
European Organisation For Research And Treatment Of Cancer
Hormone Naive Prostate Cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
1414-ROG-GUCG
Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
very high risk localized or locally advanced prostate cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
Ferring Pharmaceuticals
Prostate Cancer
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Prostate Cancer
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7 · Stage III Prostate Adenocarcinoma AJCC v7
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Memorial Sloan Kettering Cancer Center
Prostate Cancer
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
University of Washington
Stage III Prostate Adenocarcinoma AJCC v7 · Stage III Prostate Cancer AJCC v7 · Stage IV Prostate Adenocarcinoma AJCC v7 · Stage IV Prostate Cancer AJCC v7
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Prostate Cancer
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
Medical University of South Carolina
Metastatic Prostatic Adenocarcinoma
Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix
Assisting Nature
Pregnancy, Ovarian
Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.
Assisting Nature
Infertility · Premature Ovarian Failure
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
Cambridge University Hospitals NHS Foundation Trust
Prostate Cancer
Safety and Efficacy of Firmagon® (Degarelix) for Injection
Ferring Pharmaceuticals
Prostate Cancer
Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)
Chinese University of Hong Kong
Prostate Cancer
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
Ferring Pharmaceuticals
Prostate Cancer
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stage IV Prostate Cancer
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage III Prostate Cancer · Stage IV Prostate Cancer
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
The University of Texas Health Science Center, Houston
Prostatic Neoplasms
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
The University of Texas Health Science Center, Houston
Prostate Cancer
Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
Rabin Medical Center
Prostatic Neoplasms · Cardiovascular Diseases
Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Dysregulation of FSH in Obesity: Functional and Statistical Analysis
University of Colorado, Denver
Obesity · Fertility
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
Prostate Adenocarcinoma · Stage I Prostate Cancer · Stage IIA Prostate Cancer · Stage IIB Prostate Cancer
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Jonsson Comprehensive Cancer Center
Prostate Cancer
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Ferring Pharmaceuticals
Advanced Prostate Cancer
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Kenneth Pienta, MD
Prostate Cancer · Localized Prostate Cancer
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
Ferring Pharmaceuticals
Advanced Hormone Sensitive Prostate Cancer
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
Millennium Pharmaceuticals, Inc.
Prostate Cancer
Long Acting GnRH Antagonist in PCOS Women Undergoing IVF
Bioroma
Polycystic Ovarian Syndrome · Ovarian Hyperstimulation Syndrome · Invitro Fertilization
TRial on the Endocrine Activity of Neoadjuvant Degarelix
ETOP IBCSG Partners Foundation
Breast Cancer Invasive Nos
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Memorial Sloan Kettering Cancer Center
Metastatic Castration Sensitive Prostate Cancer
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
Astellas Pharma Inc
Prostate Cancer
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Prostate Adenocarcinoma · Stage IIA Prostate Cancer · Stage IIB Prostate Cancer · Stage III Prostate Cancer
Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation
Ferring Pharmaceuticals
Prostate Cancer
Impact of Estradiol Addback
Mayo Clinic
Normal Healthy Volunteers
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
Ferring Pharmaceuticals
Advanced Hormone Dependent Prostate Cancer
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Prostate Adenocarcinoma · Recurrent Prostate Carcinoma
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Adenocarcinoma in Situ
One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
Ferring Pharmaceuticals
Prostate Cancer
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Memorial Sloan Kettering Cancer Center
Prostate Cancer
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Leukemia · Multiple Myeloma · Myelodysplastic Syndrome · Non-Hodgkin's Lymphoma
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
UNICANCER
Adenocarcinoma of Prostate
Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)
Centre for Endocrinology and Reproductive Medicine, Italy
PCOS · OHSS · INFERTILITY
Degarelix in the Treatment of Endometriosis Recurrence
Centre for Endocrinology and Reproductive Medicine, Italy
Endometriosis
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
University Health Network, Toronto
Prostate Cancer
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
British Columbia Cancer Agency
Prostate Neoplasm
Treatment of Prostate Cancer With Firmagon®
United Clinic Management GmbH
Prostate Cancer
Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment
CHU de Quebec-Universite Laval
Prostate Cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
British Columbia Cancer Agency
Prostate Cancer
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Prostate Cancer · Prostatic Adenocarcinoma
Firmagon (Degarelix) Intermittent Therapy
Canadian Urology Research Consortium
Prostate Cancer Recurrent
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Degarelix Before Radical Prostatectomy
University of Cambridge
Prostate Cancer
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
M.D. Anderson Cancer Center
Prostate Cancer
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer
Ottawa Hospital Research Institute
Prostatic Neoplasms
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
Urology of Virginia
Prostate Cancer
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Study to Find Maintenance Dose for Periodic Administration of ASP3550
Astellas Pharma Inc
Prostatic Neoplasms
A Degarelix Trial in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
Ferring Pharmaceuticals
Prostate Cancer
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Prostate Cancer
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Ferring Pharmaceuticals
Prostate Cancer
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
Ferring Pharmaceuticals
Lower Urinary Tract Symptoms (LUTS)
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Effectiveness and Safety of Firmagon®
Ferring Pharmaceuticals
Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
A Trial of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
A Study of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Phase II Study of ASP3550 in Patients With Prostate Cancer
Astellas Pharma Inc
Prostatic Neoplasms
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
Ferring Pharmaceuticals
BPH
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
Ferring Pharmaceuticals
Prostate Cancer
Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix
Ferring Pharmaceuticals
Infertility, Female
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Ferring Pharmaceuticals
Prostate Cancer
Prostate Adenocarcinoma TransCutaneous Hormones
University College, London
Anemia · Cardiovascular Complications · Hot Flashes · Osteoporosis
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
Ferring Pharmaceuticals
Prostate Cancer
Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients
Ferring Pharmaceuticals
Prostate Cancer
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
Ferring Pharmaceuticals
Prostate Cancer
Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
Ferring Pharmaceuticals
Prostate Cancer
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
Ferring Pharmaceuticals
Prostate Cancer
The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Prostate Cancer
Open-Label, Randomised Parallel-Group Study
Ferring Pharmaceuticals
Prostate Cancer
PREVENT-MED
Vaestra Goetalandsregionen
Paraphilic disorder, Compulsive sexual behavior disorder
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases
ARTIC
Newly diagnosed prostate cancer with pelvic lymph nodes metastases
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
POSEIDON
Azienda Provinciale Per I Servizi Sanitari
prostate cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Degarelix is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.